Small India drugmakers struggle to meet US rules
They are under pressure to consider branching out to new, less-profitable markets or sell out to larger rivals
Mumbai
INDIA'S smaller generic drugmakers, struggling to cope with a bruised reputation and tougher regulation in the United States, are under pressure to consider branching out to new, less-profitable markets or sell out to larger rivals.
Two years after its most high-profile regulatory setback to date in the US - Ranbaxy's US$500 million fine for drug safety violations - India's US$15 billion a year generic drug industry is still rebuilding its image in its biggest market.
Many of its top firms are facing sanctions at some of their factories, as the US Food and Drug Administration (FDA) tightens checks and…
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
France's Casino supermarket chain to axe up to 3,200 jobs
Prada outshines rivals with 16% revenue lift boosted by Miu Miu
Toymaker Hasbro posts quarterly profit beat, slower sales decline
Hilton lifts 2024 profit forecast on international travel demand
China knockoff raid jolts a global throng of fake-fashion influencers
Roche cuts pipeline after research setbacks and sales drop